The use of non-steroidal anti-inflammatory drugs (NSAID) in humans reduced SI associated with insulin resistance and the risk of colon and rectal cancer by inhibiting the cyclooxygenase-2 (COX-2) pathway, tumor formation, and tumor growth11. The gene discussed is PTGS2; the disease is rectal cancer.